Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis

Cancer Research

Volumn 61, Issue 2, 2001, Pages 616-624

  Seewaldt, Victoria L ^a   Mrózek, Krzysztof ^b   Dietze, Eric C ^a   Parker, Molly ^c   Caldwell, L Elizabeth ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER PREVENTION; CANCER RISK; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE INACTIVATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TUMOR SUPPRESSOR GENE; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

APOPTOSIS; BINDING, COMPETITIVE; BLOTTING, WESTERN; BREAST; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOGENETIC ANALYSIS; DNA, RECOMBINANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EPITHELIAL CELLS; ESTROGENS; GENE EXPRESSION; GENE SILENCING; GENETIC VECTORS; GENOTYPE; HUMANS; MICROSCOPY, ELECTRON; ONCOGENE PROTEINS, VIRAL; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TAMOXIFEN; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035863522     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation
3. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice
4. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells
5. p53: From inductive signal to cellular effect
6. p53 mutations in human cancers
7. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlation with receptor status, proliferation markers, and clinical stage in human breast cancer
8. Clinical implications of the p53 tumor-suppressor gene
9. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer
10. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
11. The E 6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
12. Association of human papillomavirus types 16 and 18 E6 proteins with p53
13. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation
14. Isolation and growth of human mammary epithelial cells
15. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses
16. Expression of retinoic acid receptor β mediates retinoid-induced growth arrest and apoptosis in breast cancer cells
17. Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells
18. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7
19. 1/S-phase arrest mediated by all-trans-retinoic acid is independent of p53 expression
20. Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands
21. Immunochemical studies of estrogen receptors
22. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2
23. 1arrest but not apoptosis of normal human mammary epithelial cells
24. Inhibition of retinoic acid receptor function in normal human mammary epithelial cells results in increase proliferation and inhibition of the formation of a polarized epithelium in vitro
25. Quantification of apoptotic cells with fluorescein isothiocyanate-labeled Annexin V in Chinese hamster ovary cell culture treated with cisplatin
26. Translocation t(12;22)(q13;q12.2-12.3) in a clear cell sarcoma of tendons and aponeuroses
27. Spectral karyotyping, a 24-color FISH technique for the identification of chromosomal rearrangements
28. Multicolor spectral karyotyping of human chromosomes
29. Apoptosis oncosisnecrosis
30. Recent advances in understanding the molecular mechanisms of tamoxifen action
31. Estrogen responsiveness and control of normal human breast proliferation
32. A new, nongenomic estrogen action: The rapid release of intracellular calcium
33. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription
34. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
35. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
36. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
37. p53 status and the efficacy of cancer therapy in vivo
38. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian cancer cell lines and does not require p53
39. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53independent pathways
40. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
41. 2/M arrest and apoptosis
42. p53-independent apoptosis induced by paclitaxel through an indirect mechanism
43. Tamoxifen has a characteristic mutation spectrum in human endometrial cancer
44. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer
45. Molecular cytogenetics of primary breast cancer by CGH
46. Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers
47. Loss of heterozygosity of chromosome arm 16q in breast cancer metastases
48. Construction of a high-resolution physical and transcriptional map of chromosome 16q124.3: A region of frequent loss of heterozygosity in sporadic breast cancer
49. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast
50. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice